No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC)

Laura Capelli, Andrea Casadei Gardini, Emanuela Scarpi, Giovanni Luca Paolo Frassineti, Luca Saragoni, Maurizio Puccetti, Mario Scartozzi, Massimo Giannini, Stefano Tamberi, Jody Corbelli, Paola Ulivi

Research output: Contribution to journalArticlepeer-review

Abstract

Epidermal growth factor receptor (EGFR) is usually expressed in squamous cell anal carcinoma (SCAC) and anti-EGFR agents could represent a valid treatment strategy, also considering that KRAS and BRAF mutations are rare events in this type of cancer. However, no data are available on NRAS status in SCAC. In this study we analyzed NRAS status (exons 2-4) by Pyrosequencing in a case series of 50 SCAC patients previously characterized in our laboratory for KRAS, BRAF, PIK3CA mutations and HPV and HIV infections. We found no mutation in NRAS gene. These results confirm that since the principal anti-EGFR resistance mechanisms are almost absent in SCAC, anti-EGFR agents should be considered for the treatment of this type of cancer.

Original languageEnglish
Article number37621
JournalScientific Reports
Volume6
DOIs
Publication statusPublished - Nov 25 2016

ASJC Scopus subject areas

  • General

Fingerprint Dive into the research topics of 'No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC)'. Together they form a unique fingerprint.

Cite this